title: Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.
abstract: OBJECTIVE
  Intravenous vinflunine 320 mg/m(2) every 3 weeks plus best supportive care resulted in better overall survival in comparison with best supportive care alone for eligible patients with failure of prior therapy with locally advanced or metastatic transitional cell cancer of urothelial tract (TCCU). The objective of the present study was to describe our real-life experience of vinflunine for treatment of patients with TCCU.
  
  
  METHODS
  We retrospectively investigated all patients with TCCU who received at least 1 cycle of vinflunine.
  
  
  RESULTS
  Nineteen patients were treated between May 2010 and March 2014 in a compassionate-use program. Performance status was poor in our real-life cohort, with 6 patients (32%) with an Eastern Cooperative Oncology Group performance status of 2. Median duration of vinflunine treatment was 2.4 months (range, 0-4.3 months), and median number of cycles was 3 (range, 1-6). Total response rate was 32%, with partial responses only. Disease control rate was 53%, with a median duration of 7.7 months (range, 6.0-9.4 months). Median progression-free survival was 87 days, or 2.9 months (range, 0.7-11.7 months). After vinflunine treatment, 42% of patients received from 1 to 3 additional lines of chemotherapy. The most frequent grade 4 toxicities were constipation (26%), with 3 intestinal obstructions (16%) and 1 mechanical ileus (5%); and asthenia and fatigue (21%).
  
  
  CONCLUSIONS
  Vinflunine, as a TCCU second-line chemotherapy, brings benefits, particularly in cases where there is no alternative treatment.
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Moriceau
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Alexis
authors.initials: A
authors.lastname: Vallard
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Benoîte
authors.initials: B
authors.lastname: Méry
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Espenel
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Langrand-Escure
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Majed
authors.initials: M
authors.lastname: Ben Mrad
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Guoping
authors.initials: G
authors.lastname: Wang
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Peng
authors.initials: P
authors.lastname: Diao
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Pacaut
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Aline
authors.initials: A
authors.lastname: Guillot
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Collard
authors.affiliation: Medical Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.affiliation: Radiation Oncology Department, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France. Electronic address: nicolas.magne@icloire.fr.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D061605:Administration, Intravenous; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: C111217:vinflunine; D014747:Vinblastine
keywords: Bladder cancer; Chemotherapy; Efficacy; Tolerance; Transitional cell carcinoma